Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Common Equity (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Common Equity data on record, last reported at -$386964.0 in Q4 2025.

  • For Q4 2025, Common Equity fell 31.19% year-over-year to -$386964.0; the TTM value through Dec 2025 reached -$386964.0, down 31.19%, while the annual FY2025 figure was -$386964.0, 31.19% down from the prior year.
  • Common Equity reached -$386964.0 in Q4 2025 per ACBM's latest filing, up from -$432619.0 in the prior quarter.
  • Across five years, Common Equity topped out at $643707.0 in Q4 2021 and bottomed at -$432619.0 in Q3 2025.
  • Average Common Equity over 5 years is $118319.2, with a median of $50020.5 recorded in 2023.
  • Peak YoY movement for Common Equity: increased 2.28% in 2022, then plummeted 181.38% in 2024.
  • A 5-year view of Common Equity shows it stood at $643707.0 in 2021, then decreased by 24.44% to $486370.0 in 2022, then crashed by 152.84% to -$257014.0 in 2023, then dropped by 14.77% to -$294972.0 in 2024, then tumbled by 31.19% to -$386964.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$386964.0 in Q4 2025, -$432619.0 in Q3 2025, and -$317520.0 in Q2 2025.